Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-046468
Filing Date
2024-11-18
Accepted
2024-11-18 12:57:14
Documents
44
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 448008
2 ex31-1.htm EX-31.1 18437
3 ex31-2.htm EX-31.2 18436
4 ex32-1.htm EX-32.1 7049
5 ex32-2.htm EX-32.2 6661
  Complete submission text file 0001493152-24-046468.txt   2763280

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE nxen-20240930.xsd EX-101.SCH 21940
7 XBRL CALCULATION FILE nxen-20240930_cal.xml EX-101.CAL 25238
8 XBRL DEFINITION FILE nxen-20240930_def.xml EX-101.DEF 107956
9 XBRL LABEL FILE nxen-20240930_lab.xml EX-101.LAB 207288
10 XBRL PRESENTATION FILE nxen-20240930_pre.xml EX-101.PRE 166213
47 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 296566
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 241470609
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)